November 16, 2017
US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).
November 14, 2017
TapImmune has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer.
September 29, 2017
Peter Hoang loves being on the cutting-edge, and he believes Jacksonville-based TapImmune, Inc., which named him president and CEO Sept. 25, is there.
September 27, 2017
There are three trials that are really going to drive value for this company over the coming 24 months.
September 25, 2017
TapImmune Inc. has a new chief executive officer. Peter Hoang, the former head of business development and strategy at Bellicum Pharmaceuticals, will take over for CEO Glynn Wilson, who has been reappointed to the position of chairman of the board of directors.
August 31, 2017
Second Quarterly Call Earnings Call Transcript
August 16, 2017
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
July 24, 2017
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
July 7, 2017
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
June 7, 2017
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.